These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 5228101)

  • 1. Treatment of myeloproliferative diseases.
    Sellei C
    Ther Hung; 1966; 14(4):135-6. PubMed ID: 5228101
    [No Abstract]   [Full Text] [Related]  

  • 2. Busulphan and the lungs. Absence of lung function disturbance in patients treated with busulphan.
    Comhaire F; Van Hove W; Van Ganse W; Van der Straeten M
    Scand J Respir Dis; 1972; 53(5):265-73. PubMed ID: 4508954
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cytostatic therapy of chronic myelosis and polycythemia vera with myelobromol (dibrommannitol)].
    Helbig W; Schwenke H; Müldner J
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1969; 92(2):182-96. PubMed ID: 4189864
    [No Abstract]   [Full Text] [Related]  

  • 4. Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience.
    Begna K; Abdelatif A; Schwager S; Hanson C; Pardanani A; Tefferi A
    Blood Cancer J; 2016 May; 6(5):e427. PubMed ID: 27232929
    [No Abstract]   [Full Text] [Related]  

  • 5. [The treatment of myeloproliferative syndromes].
    Maurice P
    Schweiz Med Wochenschr; 1975 Oct; 105(40):1269-74. PubMed ID: 1061995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteration of platelets and virus-like particles by busulfan in myeloproliferative disorders.
    Fuscaldo AA; Erlick BJ; Brodsky I; Fuscaldo KE
    Leuk Res; 1980; 4(1):105-17. PubMed ID: 6157962
    [No Abstract]   [Full Text] [Related]  

  • 7. Interferon in the treatment of myeloproliferative diseases.
    Silver RT
    Semin Hematol; 1990 Jul; 27(3 Suppl 4):6-14. PubMed ID: 2115694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When to use chemotherapy for chronic hematopoietic neoplasms.
    Yu KP; Krakoff IH
    Postgrad Med; 1968 May; 43(5):176-83. PubMed ID: 5239464
    [No Abstract]   [Full Text] [Related]  

  • 9. Introduction and overview of interferon alfa in myeloproliferative and hemangiomatous diseases.
    Appelbaum FR
    Semin Hematol; 1990 Jul; 27(3 Suppl 4):1-5. PubMed ID: 2197729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chronic myeloproliferative diseases].
    Sréter L
    Orv Hetil; 1998 Jul; 139(30):1779-83. PubMed ID: 9718944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
    Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
    Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patho-anatomical features of the bone marrow.
    Lennert K; Nagai K; Schwarze EW
    Clin Haematol; 1975 Jun; 4(2):331-51. PubMed ID: 1102191
    [No Abstract]   [Full Text] [Related]  

  • 14. Chemotherapy in polycythemia vera.
    Stecher G; Reinhardt G
    Acta Genet Med Gemellol (Roma); 1968 Jan; 17(1):292-302. PubMed ID: 5241850
    [No Abstract]   [Full Text] [Related]  

  • 15. Platelet defects in the myeloproliferative disorders.
    Inceman S; Tangün Y
    Ann N Y Acad Sci; 1972 Oct; 201():251-61. PubMed ID: 4509685
    [No Abstract]   [Full Text] [Related]  

  • 16. [On the effect of a new cytostatic drug in chronic myeloses and polycythemias].
    Böhnel J; Stacher A
    Wien Med Wochenschr; 1968 Sep; 118(37):721-3. PubMed ID: 5248360
    [No Abstract]   [Full Text] [Related]  

  • 17. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Agnogenic myeloid metaplasia and polycythemia vera in the same family].
    Tosato F; Pirrone S; Manzo M; Diplotti L; Sponza E
    Haematologica; 1985; 70(3):240-1. PubMed ID: 3932153
    [No Abstract]   [Full Text] [Related]  

  • 19. [Choice of therapy and overall survival in patients with chronic myeloproliferative diseases].
    Rukavitsyn OA; Pop VP; Seriakov AP
    Vopr Onkol; 2004; 50(4):435-9. PubMed ID: 15605767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The management of elderly patients with myeloproliferative disorders.
    Tura S
    Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.